Famvir 500 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

famvir 500 mg tabletti, kalvopäällysteinen

phoenix labs - famciclovir - tabletti, kalvopäällysteinen - 500 mg - famsikloviiri

Axilur vet 250 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

axilur vet 250 mg tabletti

intervet international b.v. - fenbendazole - tabletti - 250 mg - fenbendatsoli

Axilur vet 22 % rakeet Suomi - suomi - Fimea (Suomen lääkevirasto)

axilur vet 22 % rakeet

intervet international b.v. - fenbendazole - rakeet - 22 % - fenbendatsoli

Axilur vet 500 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

axilur vet 500 mg tabletti

intervet international b.v. - fenbendazole - tabletti - 500 mg - fenbendatsoli

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

Metoprolol Orion 23.75 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metoprolol orion 23.75 mg depottabletti

orion corporation - metoprolol succinate - depottabletti - 23.75 mg - metoprololi

Metoprolol Orion 47.5 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metoprolol orion 47.5 mg depottabletti

orion corporation - metoprolol succinate - depottabletti - 47.5 mg - metoprololi

Metoprolol Orion 95 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metoprolol orion 95 mg depottabletti

orion corporation - metoprolol succinate - depottabletti - 95 mg - metoprololi

Metoprolol Orion 190 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metoprolol orion 190 mg depottabletti

orion corporation - metoprolol succinate - depottabletti - 190 mg - metoprololi

Clopidogrel BGR (previously Zylagren) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel bgr (previously zylagren)

biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - aterotromboottisten tapahtumien estämiseen klopidogreeli on tarkoitettu:aikuisille potilaille, jotka kärsivät sydäninfarkti (josta on muutama vuorokausi, mutta enintään 35 vuorokautta), iskeeminen aivohalvaus (josta on 7 vuorokautta, mutta alle 6 kuukautta) tai perifeerinen valtimosairaus.